ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-09-28

Price

$58.41

+0.05%

This is the 2026-09-28 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score5.9Watchlist

Signals4/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.8xvs 20d avg

Analysis

ATRC is exhibiting High-Conviction Price Discovery, perfectly aligning its robust technical signals (SURGE, PERFECT_STACK) with recent fundamental validation from analyst upgrades, including Stifel's price target hike to $65. Despite sensationalist geopolitical headlines, the RISK_ON macro regime—evidenced by tight 0.81% credit spreads and a compressing VIX—is encouraging structural capital rotation into resilient, high-growth MedTech names. This underlying liquidity is allowing ATRC to easily absorb short-term profit-taking and valuation skepticism, setting the stage for continued institutional accumulation.

Fired Signals

SURGEGOLDEN CROSSMARKET LEADERPERFECT STACKBARGAIN HUNTER

Key Takeaways

High-Conviction Breakout: ATRC's +20.3% 1-month surge is supported by PERFECT_STACK and MARKET_LEADER signals, confirming institutional sponsorship following recent target upgrades [1.1.7].
Macro Tailwind: The RISK_ON environment and tight credit spreads are driving a sector rotation into medical devices, insulating ATRC from broader geopolitical noise.
Valuation Headwinds: With shares up significantly, emerging media narratives questioning its EV/Sales multiple pose a minor risk of profit-taking near current highs.

← Back to 2026-09-28 View Full ATRC History →Yahoo Finance &nearr;